Lung Cancer Trial, Recruiting (NCT06247826)

Lung Cancer Trial, Recruiting NCT06247826 Sponsor: Groupe Francais De Pneumo-Cancerologie Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06247826 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed or treated with radiotherapy
Your cancer has a specific genetic change called EGFR insertion 20 (a mutation in the EGFR gene)
You are 18 years of age or older
You are receiving or have received a drug called amivantamab on its own (not combined with other cancer treatments) in France through a special early access programme
Your cancer has been confirmed to have started growing again or spreading while on amivantamab treatment
Your lung cancer diagnosis was confirmed through a tissue sample (biopsy) examined in a laboratory
You are covered by the French National Health Insurance programme or have another recognised health coverage
You are willing to sign a consent form and agree to provide a blood sample (called a liquid biopsy) when your cancer progresses, and a tissue sample if one is available at that time

Who may not be able to join:

You are taking amivantamab alongside any other cancer treatment (it must be taken alone)
You do not agree to provide a blood sample (liquid biopsy) when your cancer progresses

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 30 June 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06247826

Sponsor: Groupe Francais De Pneumo-Cancerologie

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

More information: https://clinicaltrials.gov/study/NCT06247826

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed or treated with radiotherapy
Your cancer has a specific genetic change called EGFR insertion 20 (a mutation in the EGFR gene)
You are 18 years of age or older
You are receiving or have received a drug called amivantamab on its own (not combined with other cancer treatments) in France through a special early access programme
Your cancer has been confirmed to have started growing again or spreading while on amivantamab treatment
Your lung cancer diagnosis was confirmed through a tissue sample (biopsy) examined in a laboratory
You are covered by the French National Health Insurance programme or have another recognised health coverage
You are willing to sign a consent form and agree to provide a blood sample (called a liquid biopsy) when your cancer progresses, and a tissue sample if one is available at that time

Who may not be able to join:

You are taking amivantamab alongside any other cancer treatment (it must be taken alone)
You do not agree to provide a blood sample (liquid biopsy) when your cancer progresses

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 30 June 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Groupe Francais De Pneumo-Cancerologie

Registry

ClinicalTrials.gov

Start date

15 January 2024

Est. completion

30 July 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Percentage of molecular alterations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov